<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neuren Pharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd</link>
<description>Latest news and press releases for Neuren Pharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:09:04 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neuren-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<item>
<title>DAYBUE STIX now broadly available in US for Rett syndrome</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-stix-now-broadly-available-in-us-for-rett-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-stix-now-broadly-available-in-us-for-rett-syndrome</guid>
<pubDate>Wed, 08 Apr 2026 04:09:04 GMT</pubDate>
<description>DAYBUE STIX now broadly available in US for Rett syndrome</description>
</item>
<item>
<title>Acadia confirms plan to request CHMP re-examination</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-confirms-plan-to-request-chmp-re-examination</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-confirms-plan-to-request-chmp-re-examination</guid>
<pubDate>Tue, 03 Mar 2026 04:10:10 GMT</pubDate>
<description>Acadia confirms plan to request CHMP re-examination</description>
</item>
<item>
<title>2025 royalty income A$65m, profit after tax A$30m</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/2025-royalty-income-adollar65m-profit-after-tax-adollar30m</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/2025-royalty-income-adollar65m-profit-after-tax-adollar30m</guid>
<pubDate>Fri, 27 Feb 2026 04:19:19 GMT</pubDate>
<description>2025 royalty income A$65m, profit after tax A$30m</description>
</item>
<item>
<title>Appendix 4E and 2025 full year accounts</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/appendix-4e-and-2025-full-year-accounts</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/appendix-4e-and-2025-full-year-accounts</guid>
<pubDate>Fri, 27 Feb 2026 04:13:19 GMT</pubDate>
<description>Appendix 4E and 2025 full year accounts</description>
</item>
<item>
<title>Acadia reports DAYBUE net sales for 2025 and 2026 guidance</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-reports-daybue-net-sales-for-2025-and-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-reports-daybue-net-sales-for-2025-and-2026-guidance</guid>
<pubDate>Thu, 26 Feb 2026 05:39:09 GMT</pubDate>
<description>Acadia reports DAYBUE net sales for 2025 and 2026 guidance</description>
</item>
<item>
<title>Pause in Trading</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/pause-in-trading-53</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/pause-in-trading-53</guid>
<pubDate>Thu, 26 Feb 2026 04:13:18 GMT</pubDate>
<description>Pause in Trading</description>
</item>
<item>
<title>Neuren to commence new on-market share buy-back program</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-to-commence-new-on-market-share-buy-back-program</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-to-commence-new-on-market-share-buy-back-program</guid>
<pubDate>Wed, 11 Feb 2026 11:21:03 GMT</pubDate>
<description>Neuren to commence new on-market share buy-back program</description>
</item>
<item>
<title>First patient dosed in Neuren PMS Phase 3 trial</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/first-patient-dosed-in-neuren-pms-phase-3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/first-patient-dosed-in-neuren-pms-phase-3-trial</guid>
<pubDate>Fri, 06 Feb 2026 03:46:06 GMT</pubDate>
<description>First patient dosed in Neuren PMS Phase 3 trial</description>
</item>
<item>
<title>Neuren receives US FDA meeting feeback for HIE and PTHS</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-receives-us-fda-meeting-feeback-for-hie-and-pths</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-receives-us-fda-meeting-feeback-for-hie-and-pths</guid>
<pubDate>Wed, 04 Feb 2026 11:28:04 GMT</pubDate>
<description>Neuren receives US FDA meeting feeback for HIE and PTHS</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/trading-halt-97</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/trading-halt-97</guid>
<pubDate>Wed, 04 Feb 2026 04:35:03 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Acadia provides update on EU regulatory submission</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-provides-update-on-eu-regulatory-submission</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/acadia-provides-update-on-eu-regulatory-submission</guid>
<pubDate>Tue, 03 Feb 2026 04:01:05 GMT</pubDate>
<description>Acadia provides update on EU regulatory submission</description>
</item>
<item>
<title>Response to ASX Aware Letter</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/response-to-asx-aware-letter-16</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/response-to-asx-aware-letter-16</guid>
<pubDate>Mon, 19 Jan 2026 03:31:05 GMT</pubDate>
<description>Response to ASX Aware Letter</description>
</item>
<item>
<title>DAYBUE net sales projected to reach approx US$700m in 2028</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-net-sales-projected-to-reach-approx-usdollar700m-in-2028</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-net-sales-projected-to-reach-approx-usdollar700m-in-2028</guid>
<pubDate>Wed, 14 Jan 2026 04:47:03 GMT</pubDate>
<description>DAYBUE net sales projected to reach approx US$700m in 2028</description>
</item>
<item>
<title>FDA approves DAYBUE STIX (trofinetide), powder formulation</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/fda-approves-daybue-stix-trofinetide-powder-formulation</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/fda-approves-daybue-stix-trofinetide-powder-formulation</guid>
<pubDate>Mon, 15 Dec 2025 03:26:07 GMT</pubDate>
<description>FDA approves DAYBUE STIX (trofinetide), powder formulation</description>
</item>
<item>
<title>Record DAYBUE net sales of US$101.1 million in Q3 2025</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/record-daybue-net-sales-of-usdollar1011-million-in-q3-2025</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/record-daybue-net-sales-of-usdollar1011-million-in-q3-2025</guid>
<pubDate>Thu, 06 Nov 2025 04:19:14 GMT</pubDate>
<description>Record DAYBUE net sales of US$101.1 million in Q3 2025</description>
</item>
<item>
<title>Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/fast-track-granted-by-fda-for-nnz-2591-in-phelan-mcdermid</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/fast-track-granted-by-fda-for-nnz-2591-in-phelan-mcdermid</guid>
<pubDate>Mon, 20 Oct 2025 02:49:18 GMT</pubDate>
<description>Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/half-yearly-report-and-accounts-59</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/half-yearly-report-and-accounts-59</guid>
<pubDate>Wed, 27 Aug 2025 03:41:18 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>First site initiated for Neuren's PMS Phase 3 trial</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/first-site-initiated-for-neurens-pms-phase-3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/first-site-initiated-for-neurens-pms-phase-3-trial</guid>
<pubDate>Mon, 25 Aug 2025 03:47:29 GMT</pubDate>
<description>First site initiated for Neuren's PMS Phase 3 trial</description>
</item>
<item>
<title>Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-adds-syngap1-related-disorder-to-nnz-2591-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/neuren-adds-syngap1-related-disorder-to-nnz-2591-pipeline</guid>
<pubDate>Fri, 08 Aug 2025 03:37:16 GMT</pubDate>
<description>Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline</description>
</item>
<item>
<title>DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024</title>
<link>https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-q2-2025-net-sales-usdollar961-million-up-14percent-from-q2-2024</link>
<guid isPermaLink="true">https://6ix.com/company/neuren-pharmaceuticals-ltd/news/daybue-q2-2025-net-sales-usdollar961-million-up-14percent-from-q2-2024</guid>
<pubDate>Thu, 07 Aug 2025 04:12:18 GMT</pubDate>
<description>DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024</description>
</item>
</channel>
</rss>